董事介绍
注:董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jason M. Hollar | 男 | Chief Executive Officer and Director | 53 | 1897.62万美元 | 5.39 | 2026-03-20 |
| Robert W. Azelby | 男 | Independent Director | 58 | 32.20万美元 | 0.30 | 2026-03-20 |
| Michelle M. Brennan | 女 | Independent Director | 61 | 32.00万美元 | 0.70 | 2026-03-20 |
| Christine A. Mundkur | 女 | Independent Director | 57 | 32.00万美元 | 0.65 | 2026-03-20 |
| Robert W. Musslewhite | 男 | Independent Director | 56 | 17.25万美元 | 未持股 | 2026-03-20 |
| David C. Evans | 男 | Independent Director | 63 | 32.20万美元 | 1.43 | 2026-03-20 |
| Sheri H. Edison | 女 | Independent Director | 69 | 34.00万美元 | 1.38 | 2026-03-20 |
| Patricia A. Hemingway Hall | 女 | Independent Chairman of the Board | 73 | 34.20万美元 | 2.86 | 2026-03-20 |
| Akhil Johri | 男 | Independent Director | 65 | 34.70万美元 | 2.18 | 2026-03-20 |
| Nancy Killefer | 女 | Independent Director | 72 | 34.00万美元 | 2.66 | 2026-03-20 |
| Sudhakar Ramakrishna | 男 | Independent Director | 58 | 17.25万美元 | 未持股 | 2026-03-20 |
高管介绍
注:高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jason M. Hollar | 男 | Chief Executive Officer and Director | 53 | 1897.62万美元 | 5.39 | 2026-03-20 |
| Stephen M. Mason | 男 | Chief Executive Officer, GMPD segment | 55 | 474.50万美元 | 0.47 | 2026-03-20 |
| Deborah L. Weitzman | 女 | Chief Executive Officer, Pharma segment | 61 | 550.79万美元 | 2.87 | 2026-03-20 |
| Aaron E. Alt | 男 | Chief Financial Officer | 55 | 621.00万美元 | 未持股 | 2026-03-20 |
| Ola M. Snow | 女 | Chief Human Resources Officer | 59 | 未披露 | 未持股 | 2026-03-20 |
| Jessica L. Mayer | 女 | Chief Legal and Compliance Officer | 57 | 492.54万美元 | 2.72 | 2026-03-20 |
| Michelle D. Greene | 女 | Executive Vice President, Chief Information Officer and Customer Support Services | 56 | 未披露 | 未持股 | 2026-03-20 |
| Mary C. Scherer | -- | Senior Vice President and Chief Accounting Officer | -- | 未披露 | 未持股 | 2026-03-20 |
董事简历
中英对照 |  中文 |  英文- Jason M. Hollar
-
Jason M. Hollar, Cardinal Health首席执行官(自2022年起)。Cardinal Health首席财务官(2020 - 2022)。Tenneco Inc.(全球汽车产品和服务公司)的执行副总裁兼首席财务官(2018 - 2020)。Tenneco Inc.高级财务副总裁(2017 - 2018)。西尔斯控股公司(Sears Holding Corporation),一家美国大型消费零售商的控股公司(Sears于2018年10月申请破产保护)。他还曾担任Delphi Automotive's powertrain systems division的公司财务总监和财务副总裁,负责监督欧洲、中东和非洲地区。在职业生涯早期,他曾在Navistar的发动机集团、南美业务以及公司财务规划和分析担任财务职位,责任越来越大。
Jason M. Hollar,has served as Chief Executive Officer since September 2022. From May 2020 through August 2022, Mr. Hollar served as Chief Financial Officer. Additionally, Mr. Hollar served as Chief Financial Officer of Sears Holding Corporation ("Sears") from October 2016 to April 2017. Sears filed for Chapter 11 bankruptcy in October 2018. - Jason M. Hollar, Cardinal Health首席执行官(自2022年起)。Cardinal Health首席财务官(2020 - 2022)。Tenneco Inc.(全球汽车产品和服务公司)的执行副总裁兼首席财务官(2018 - 2020)。Tenneco Inc.高级财务副总裁(2017 - 2018)。西尔斯控股公司(Sears Holding Corporation),一家美国大型消费零售商的控股公司(Sears于2018年10月申请破产保护)。他还曾担任Delphi Automotive's powertrain systems division的公司财务总监和财务副总裁,负责监督欧洲、中东和非洲地区。在职业生涯早期,他曾在Navistar的发动机集团、南美业务以及公司财务规划和分析担任财务职位,责任越来越大。
- Jason M. Hollar,has served as Chief Executive Officer since September 2022. From May 2020 through August 2022, Mr. Hollar served as Chief Financial Officer. Additionally, Mr. Hollar served as Chief Financial Officer of Sears Holding Corporation ("Sears") from October 2016 to April 2017. Sears filed for Chapter 11 bankruptcy in October 2018.
- Robert W. Azelby
-
Robert W. Azelby,MBA,自2017年4月起担任卡地纳健康董事会成员。阿泽尔比先生是卡地纳健康公司治理和提名委员会的成员。自2015年11月起,Azelby先生在生物技术公司Juno Therapeutics, Inc.担任执行副总裁兼首席商务官。在加入Juno之前,Azelby先生于2012年6月至2015年10月在安进公司担任肿瘤科副总裁兼总经理。2010年10月至2012年9月,担任安进的副总裁,负责安进肿瘤学销售。在此之前,他曾在安进担任多个职位,包括期间担任副总裁、商业效能单位以及安进荷兰公司总经理。阿泽尔比在弗吉尼亚大学获得经济学和宗教研究学士学位,在哈佛商学院获得工商管理硕士学位。
Robert W. Azelby,President and CEO of Eliem Therapeutics, Inc., a biotechnology company focused on neuronal excitability disorders (2020 – 2023).President and CEO of Alder BioPharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on prevention of chronic migraines (2018 – 2019).Executive Vice President and Chief Commercial Officer of Juno Therapeutics Inc., a biopharmaceutical company (2015 – 2018).Held various senior roles at Amgen, a multinational biopharmaceutical company (2000 – 2015). - Robert W. Azelby,MBA,自2017年4月起担任卡地纳健康董事会成员。阿泽尔比先生是卡地纳健康公司治理和提名委员会的成员。自2015年11月起,Azelby先生在生物技术公司Juno Therapeutics, Inc.担任执行副总裁兼首席商务官。在加入Juno之前,Azelby先生于2012年6月至2015年10月在安进公司担任肿瘤科副总裁兼总经理。2010年10月至2012年9月,担任安进的副总裁,负责安进肿瘤学销售。在此之前,他曾在安进担任多个职位,包括期间担任副总裁、商业效能单位以及安进荷兰公司总经理。阿泽尔比在弗吉尼亚大学获得经济学和宗教研究学士学位,在哈佛商学院获得工商管理硕士学位。
- Robert W. Azelby,President and CEO of Eliem Therapeutics, Inc., a biotechnology company focused on neuronal excitability disorders (2020 – 2023).President and CEO of Alder BioPharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on prevention of chronic migraines (2018 – 2019).Executive Vice President and Chief Commercial Officer of Juno Therapeutics Inc., a biopharmaceutical company (2015 – 2018).Held various senior roles at Amgen, a multinational biopharmaceutical company (2000 – 2015).
- Michelle M. Brennan
-
Michelle M. Brennan在强生担任多个职位,职责不断增加,她在医疗保健和消费品领域担任研究员、开发商和制造商超过32年,最近于2019年1月至2020年8月担任全球价值创造负责人。2015年至2018年12月,她担任欧洲、中东和非洲“EMEA”医疗器械公司集团主席,2007年至2014年,她担任过多个高级管理职位,包括企业标准和生产力总裁、Ethicon Energy全球总裁,Ethicon Endo Surgery欧洲、中东和非洲、地中海和伊比利亚地区总裁,Ethicon Endo Surgery业务发展与战略全球副总裁。
Michelle M. Brennan,Global Value Creation Leader at J&J, a researcher, developer, and manufacturer in the healthcare and consumer packaged goods fields (2019 – 2020).Company Group Chair of Medical Devices at J&J in Europe, the Middle East, and Africa ("EMEA") (2015 – 2018).President of Enterprise Standards & Productivity at J&J (2014 – 2015).Worldwide President of Ethicon Energy at J&J (2012 – 2014).Regional President of Ethicon Endo Surgery for EMEA, the Mediterranean, and Iberia, at J&J (2010 – 2012).Worldwide Vice President of Business Development & Strategy for Ethicon Endo Surgery at J&J (2007 – 2009). - Michelle M. Brennan在强生担任多个职位,职责不断增加,她在医疗保健和消费品领域担任研究员、开发商和制造商超过32年,最近于2019年1月至2020年8月担任全球价值创造负责人。2015年至2018年12月,她担任欧洲、中东和非洲“EMEA”医疗器械公司集团主席,2007年至2014年,她担任过多个高级管理职位,包括企业标准和生产力总裁、Ethicon Energy全球总裁,Ethicon Endo Surgery欧洲、中东和非洲、地中海和伊比利亚地区总裁,Ethicon Endo Surgery业务发展与战略全球副总裁。
- Michelle M. Brennan,Global Value Creation Leader at J&J, a researcher, developer, and manufacturer in the healthcare and consumer packaged goods fields (2019 – 2020).Company Group Chair of Medical Devices at J&J in Europe, the Middle East, and Africa ("EMEA") (2015 – 2018).President of Enterprise Standards & Productivity at J&J (2014 – 2015).Worldwide President of Ethicon Energy at J&J (2012 – 2014).Regional President of Ethicon Endo Surgery for EMEA, the Mediterranean, and Iberia, at J&J (2010 – 2012).Worldwide Vice President of Business Development & Strategy for Ethicon Endo Surgery at J&J (2007 – 2009).
- Christine A. Mundkur
-
Christine A. Mundkur最近于2013年至2017年担任仿制药吸入开发公司Impopharma Inc.的首席执行官和无投票权的董事会主席。在此之前,她曾担任CM Strategic Advisors总裁,于2011年至2013年担任全球制药业务战略咨询。Mundkur女士还曾于2009年至2010年担任Sandoz,Inc.美国分部总裁兼首席执行官以及北美商业运营主管,Sandoz,Inc.是诺华集团的一个部门,也是一家全球仿制药和生物仿制药业务。在此之前,她于2008年担任Barr Pharmaceuticals,Inc.的子公司Barr Laboratories,Inc.的首席执行官,在Barr Pharmaceuticals被梯瓦制药有限公司收购之前,Mundkur女士于1993年在Barr Pharmaceuticals开始了她的职业生涯,担任副法律顾问,并在卡地纳健康集团的质量和监管部门担任过多个职位。
Christine A. Mundkur,CEO and non-voting Chair of the Board of Directors at Impopharma Inc., a generic pharmaceutical inhalation development company (2013 – 2017).President of CM Strategic Advisors, consulting on global pharmaceutical business strategies (2011 – 2013).President and CEO of the U.S. Division and Head of Commercial Operations for North America for Sandoz, Inc., a division of the Novartis Group and a global generic and biosimilar pharmaceutical business (2009 – 2010).CEO of Barr Laboratories, Inc., a subsidiary of Barr Pharmaceuticals, Inc. (2008).Associate Counsel at Barr Pharmaceuticals and held several positions of increasing responsibility in the company's quality and regulatory departments (1993 – 2008). - Christine A. Mundkur最近于2013年至2017年担任仿制药吸入开发公司Impopharma Inc.的首席执行官和无投票权的董事会主席。在此之前,她曾担任CM Strategic Advisors总裁,于2011年至2013年担任全球制药业务战略咨询。Mundkur女士还曾于2009年至2010年担任Sandoz,Inc.美国分部总裁兼首席执行官以及北美商业运营主管,Sandoz,Inc.是诺华集团的一个部门,也是一家全球仿制药和生物仿制药业务。在此之前,她于2008年担任Barr Pharmaceuticals,Inc.的子公司Barr Laboratories,Inc.的首席执行官,在Barr Pharmaceuticals被梯瓦制药有限公司收购之前,Mundkur女士于1993年在Barr Pharmaceuticals开始了她的职业生涯,担任副法律顾问,并在卡地纳健康集团的质量和监管部门担任过多个职位。
- Christine A. Mundkur,CEO and non-voting Chair of the Board of Directors at Impopharma Inc., a generic pharmaceutical inhalation development company (2013 – 2017).President of CM Strategic Advisors, consulting on global pharmaceutical business strategies (2011 – 2013).President and CEO of the U.S. Division and Head of Commercial Operations for North America for Sandoz, Inc., a division of the Novartis Group and a global generic and biosimilar pharmaceutical business (2009 – 2010).CEO of Barr Laboratories, Inc., a subsidiary of Barr Pharmaceuticals, Inc. (2008).Associate Counsel at Barr Pharmaceuticals and held several positions of increasing responsibility in the company's quality and regulatory departments (1993 – 2008).
- Robert W. Musslewhite
-
Robert W. Musslewhite自2021年10月起担任Definitive Healthcare总裁。在此之前,Musslewhite先生于2019年8月开始担任OptumInsight的首席执行官,OptumInsight是Optum的健康服务业务,将医疗保健系统与旨在使临床和行政流程更简单、更高效的服务、分析和平台连接起来。他在Optum收购The Advisory Board Company后加入Optum,The Advisory Board Company是一家上市公司,提供最佳实践研究和洞察、技术、数据支持服务和咨询服务,2008年至2017年担任首席执行官,2013年至2017年担任董事长。在被任命为OptumInsight的首席执行官之前,Musslewhite先生曾于2019年3月至2019年8月担任Optum360的首席执行官,Optum360是医疗保健行业的收入周期管理提供商,在此之前,他曾担任OptumAnalytics的首席执行官,医疗保健行业数据和分析提供商,2017年至2019年3月担任医疗保健研究和最佳实践提供商Advisory Board Research的首席执行官。在加入The Advisory Board Company之前,Musslewhite先生是麦肯锡公司的副校长,麦肯锡公司是一家全球性管理咨询公司,在华盛顿特区、阿姆斯特丹和达拉斯设有办事处。Musslewhite先生目前担任私人公司Ascend Learning的董事会成员。Musslewhite先生在哈佛大学法学院获得法学博士学位,在普林斯顿大学获得经济学学士学位。
Robert W. Musslewhite,served as CEO of Definitive Healthcare from August 2022 to January 2024, and was previously appointed as its President in October 2021. Prior, Mr. Musslewhite served as the CEO of OptumInsight, Optum's health services business connecting the health care system with services, analytics, and platforms designed to make clinical and administrative processes easier and more efficient, beginning in 2019. While at Optum, prior to leading OptumInsight, Mr. Musslewhite was CEO of Optum360, CEO of Optum Analytics and CEO of Advisory Board Research. Mr. Musslewhite joined Optum in 2017, following its acquisition of the Advisory Board Company where he served as CEO since 2008 and Chairman since 2013. Prior to joining The Advisory Board Company, Mr. Musslewhite was an Associate Principal with McKinsey & Company, a global management consulting firm, in the Washington, D.C., Amsterdam, and Dallas offices.Education:B.A. (Economics), Princeton University;J.D., Harvard Law School. - Robert W. Musslewhite自2021年10月起担任Definitive Healthcare总裁。在此之前,Musslewhite先生于2019年8月开始担任OptumInsight的首席执行官,OptumInsight是Optum的健康服务业务,将医疗保健系统与旨在使临床和行政流程更简单、更高效的服务、分析和平台连接起来。他在Optum收购The Advisory Board Company后加入Optum,The Advisory Board Company是一家上市公司,提供最佳实践研究和洞察、技术、数据支持服务和咨询服务,2008年至2017年担任首席执行官,2013年至2017年担任董事长。在被任命为OptumInsight的首席执行官之前,Musslewhite先生曾于2019年3月至2019年8月担任Optum360的首席执行官,Optum360是医疗保健行业的收入周期管理提供商,在此之前,他曾担任OptumAnalytics的首席执行官,医疗保健行业数据和分析提供商,2017年至2019年3月担任医疗保健研究和最佳实践提供商Advisory Board Research的首席执行官。在加入The Advisory Board Company之前,Musslewhite先生是麦肯锡公司的副校长,麦肯锡公司是一家全球性管理咨询公司,在华盛顿特区、阿姆斯特丹和达拉斯设有办事处。Musslewhite先生目前担任私人公司Ascend Learning的董事会成员。Musslewhite先生在哈佛大学法学院获得法学博士学位,在普林斯顿大学获得经济学学士学位。
- Robert W. Musslewhite,served as CEO of Definitive Healthcare from August 2022 to January 2024, and was previously appointed as its President in October 2021. Prior, Mr. Musslewhite served as the CEO of OptumInsight, Optum's health services business connecting the health care system with services, analytics, and platforms designed to make clinical and administrative processes easier and more efficient, beginning in 2019. While at Optum, prior to leading OptumInsight, Mr. Musslewhite was CEO of Optum360, CEO of Optum Analytics and CEO of Advisory Board Research. Mr. Musslewhite joined Optum in 2017, following its acquisition of the Advisory Board Company where he served as CEO since 2008 and Chairman since 2013. Prior to joining The Advisory Board Company, Mr. Musslewhite was an Associate Principal with McKinsey & Company, a global management consulting firm, in the Washington, D.C., Amsterdam, and Dallas offices.Education:B.A. (Economics), Princeton University;J.D., Harvard Law School.
- David C. Evans
-
David C. Evans,他于2011年1月担任Scotts Miracle-Gro公司的财务总监和执行副总裁,负责战略和业务发展事务。自2006年9月,他在Scotts Miracle-Gro公司担任执行副总裁和财务总监。自2005年10月至2006年9月,他担任Scotts公司的高级副总裁,负责金融和全球共享服务。
David C. Evans is a director of Cardinal Health Inc. ("Cardinal Health"), a global integrated healthcare services and products company. Mr. Evans serves on the Audit (Chair) and Human Resce and Compensation Committees at Cardinal Health. Mr. Evans served as Executive Vice President & Interim Chief Financial Officer of the Company from Augt 2022 until November 2022. Mr. Evans served as the Interim Chief Financial Officer of Cardinal Health from September 2019 until May 2020, after a transition role beginning in July 2019. Mr. Evans previoly served as Executive Vice President and Chief Financial Officer of Battelle Memorial Institute ("Battelle"), a private research and development organization, from March 2013 until January 2018. Mr. Evans' responsibilities at Battelle included strategy, information technology and cybersecurity. Prior to joining Battelle, Mr. Evans served in vario managerial roles at the Company, including, most recently, Chief Financial Officer and Executive Vice President, Strategy and Biness Development from September 2006 until February 2013. - David C. Evans,他于2011年1月担任Scotts Miracle-Gro公司的财务总监和执行副总裁,负责战略和业务发展事务。自2006年9月,他在Scotts Miracle-Gro公司担任执行副总裁和财务总监。自2005年10月至2006年9月,他担任Scotts公司的高级副总裁,负责金融和全球共享服务。
- David C. Evans is a director of Cardinal Health Inc. ("Cardinal Health"), a global integrated healthcare services and products company. Mr. Evans serves on the Audit (Chair) and Human Resce and Compensation Committees at Cardinal Health. Mr. Evans served as Executive Vice President & Interim Chief Financial Officer of the Company from Augt 2022 until November 2022. Mr. Evans served as the Interim Chief Financial Officer of Cardinal Health from September 2019 until May 2020, after a transition role beginning in July 2019. Mr. Evans previoly served as Executive Vice President and Chief Financial Officer of Battelle Memorial Institute ("Battelle"), a private research and development organization, from March 2013 until January 2018. Mr. Evans' responsibilities at Battelle included strategy, information technology and cybersecurity. Prior to joining Battelle, Mr. Evans served in vario managerial roles at the Company, including, most recently, Chief Financial Officer and Executive Vice President, Strategy and Biness Development from September 2006 until February 2013.
- Sheri H. Edison
-
Sheri H. Edison从2010年至今担任副总裁、总法律顾问和秘书。从2007年到2010年担任Hill-Rom, Inc.的高级副总裁兼首席行政官。从2003年至2007年担任Hill-Rom, Inc.的副总裁、总法律顾问和秘书。
Sheri H. Edison,Executive Vice President and General Counsel of Amcor plc, a global packaging company (2019 – 2021).Senior Vice President, Chief Legal Officer, and Secretary of Bemis Company, Inc., a global packaging company (from 2017 until Bemis was acquired by Amcor in 2019).Vice President, General Counsel, and Secretary of Bemis (2010 – 2016).Senior Vice President and Chief Administrative Officer of Hill-Rom Holdings Inc., a global medical device company (2007 – 2010).Vice President, General Counsel, and Secretary of Hill-Rom Holdings Inc. (2004 – 2007).Began career in private legal practice. - Sheri H. Edison从2010年至今担任副总裁、总法律顾问和秘书。从2007年到2010年担任Hill-Rom, Inc.的高级副总裁兼首席行政官。从2003年至2007年担任Hill-Rom, Inc.的副总裁、总法律顾问和秘书。
- Sheri H. Edison,Executive Vice President and General Counsel of Amcor plc, a global packaging company (2019 – 2021).Senior Vice President, Chief Legal Officer, and Secretary of Bemis Company, Inc., a global packaging company (from 2017 until Bemis was acquired by Amcor in 2019).Vice President, General Counsel, and Secretary of Bemis (2010 – 2016).Senior Vice President and Chief Administrative Officer of Hill-Rom Holdings Inc., a global medical device company (2007 – 2010).Vice President, General Counsel, and Secretary of Hill-Rom Holdings Inc. (2004 – 2007).Began career in private legal practice.
- Patricia A. Hemingway Hall
-
Patricia A. Hemingway Hall自2008年11月担任健康护理服务公司(Health Care Service Corporation)的总裁以及首席执行官。从2007年11月到2008年11月担任健康护理服务公司(Health Care Service Corporation)的总裁以及首席运营官。从2006年到2007年担任健康护理服务公司(Health Care Service Corporation)负责内部运营的执行副总裁。此前,自1998年她还在健康护理服务公司(Health Care Service Corporation)担任其它高级管理类职务。自2011年5月担任ManpowerGroup集团董事。自2013年11月担任心脏健康公司(Cardinal Health)董事。在过去5年中没有其它担任上市公司领导的任职经历。
Patricia A. Hemingway Hall,President and CEO of HCSC (2008 – 2016).President and Chief Operating Officer of HCSC (2007 – 2008).Executive Vice President of Internal Operations of HCSC (2006 – 2007). - Patricia A. Hemingway Hall自2008年11月担任健康护理服务公司(Health Care Service Corporation)的总裁以及首席执行官。从2007年11月到2008年11月担任健康护理服务公司(Health Care Service Corporation)的总裁以及首席运营官。从2006年到2007年担任健康护理服务公司(Health Care Service Corporation)负责内部运营的执行副总裁。此前,自1998年她还在健康护理服务公司(Health Care Service Corporation)担任其它高级管理类职务。自2011年5月担任ManpowerGroup集团董事。自2013年11月担任心脏健康公司(Cardinal Health)董事。在过去5年中没有其它担任上市公司领导的任职经历。
- Patricia A. Hemingway Hall,President and CEO of HCSC (2008 – 2016).President and Chief Operating Officer of HCSC (2007 – 2008).Executive Vice President of Internal Operations of HCSC (2006 – 2007).
- Akhil Johri
-
Akhil Johri,Dubilier&Rice 2021运营顾问-现在,特别的联合技术公司董事长兼首席执行官顾问(2019-2020)。自2013年5月以来,他一直担任首席财务官。加入美国颇尔之前, 他任职美国联合技术公司26年,并担任多种行政职位,责任也越来越大。他最近担任UTC Propulsion and Aerospace Systems的财务副总裁和首席财务官(从2011年11月到2013年4月),以及副总裁,负责财务规划和投资者关系(从2009年5月到2011年10月)。
Akhil Johri,Operating Advisor, Clayton, Dubilier & Rice (2021-present);Special Advisor to the Chairman and CEO, United Technologies Corporation (2019-2020);Executive Vice President and CFO, United Technologies Corporation (2015-2019);CFO, Pall Corporation (2013-2014);Vice President, Finance and CFO, UTC Propulsion and Aerospace Systems, United Technologies Corporation (2011-2013);Vice President, Financial Planning and Investor Relations, United Technologies Corporation (2009-2011). - Akhil Johri,Dubilier&Rice 2021运营顾问-现在,特别的联合技术公司董事长兼首席执行官顾问(2019-2020)。自2013年5月以来,他一直担任首席财务官。加入美国颇尔之前, 他任职美国联合技术公司26年,并担任多种行政职位,责任也越来越大。他最近担任UTC Propulsion and Aerospace Systems的财务副总裁和首席财务官(从2011年11月到2013年4月),以及副总裁,负责财务规划和投资者关系(从2009年5月到2011年10月)。
- Akhil Johri,Operating Advisor, Clayton, Dubilier & Rice (2021-present);Special Advisor to the Chairman and CEO, United Technologies Corporation (2019-2020);Executive Vice President and CFO, United Technologies Corporation (2015-2019);CFO, Pall Corporation (2013-2014);Vice President, Finance and CFO, UTC Propulsion and Aerospace Systems, United Technologies Corporation (2011-2013);Vice President, Financial Planning and Investor Relations, United Technologies Corporation (2009-2011).
- Nancy Killefer
-
Nancy Killefer自2013年9月以来担任卡地纳健康集团的董事会成员。她1992年到2013年8月担任McKinsey & Company(国际管理咨询公司)的董事。她目前是ctor Emeritus at McKinsey & Company的名誉董事。她于1979年加McKinsey & Company,担任许多领导角色,包括担任公司董事会的成员。她领导公司的招聘工作,是公司的几个人事委员会的主席。从2000年到2007年她经营McKinsey & Company的华盛顿特区办事处。从1997年到2000年她担任美国财政部(the U.S. Department of the Treasury)的管理部长助理、首席财务官和首席运营官。2000年她回到McKinsey & Company,建立并领导公司的公共部门实践。她还从2000年到2005年担任美国国税局监督委员会(IRS Oversight Board)的成员,从2002年到2004年担任其主席。她目前是Avon Products Inc.和Computer Sciences Corporation的董事,两者都在纽约证券交易所(New York Stock Exchange)上市。她获得瓦萨尔学院(Vassar College)的学士学位和麻省理工学院斯隆管理学院(MIT Sloan School of Management)的工商管理硕士学位。
Nancy Killefer,McKinsey & Company (international management consulting firm):Senior Partner (1992-2013),Governing Board Member (2000-2006 and 2007-2013),Head and Founder of global public sector practice (2005-2012),Head of Washington, D.C. office (2000-2007),Various other positions (1979-1992);U.S. Department of the Treasury:Assistant Secretary for Management, Chief Financial Officer & Chief Operating Officer (1997-2000);Education:Vassar College (B.A. in economics),Massachusetts Institute of Technology (M.S.M. in finance). - Nancy Killefer自2013年9月以来担任卡地纳健康集团的董事会成员。她1992年到2013年8月担任McKinsey & Company(国际管理咨询公司)的董事。她目前是ctor Emeritus at McKinsey & Company的名誉董事。她于1979年加McKinsey & Company,担任许多领导角色,包括担任公司董事会的成员。她领导公司的招聘工作,是公司的几个人事委员会的主席。从2000年到2007年她经营McKinsey & Company的华盛顿特区办事处。从1997年到2000年她担任美国财政部(the U.S. Department of the Treasury)的管理部长助理、首席财务官和首席运营官。2000年她回到McKinsey & Company,建立并领导公司的公共部门实践。她还从2000年到2005年担任美国国税局监督委员会(IRS Oversight Board)的成员,从2002年到2004年担任其主席。她目前是Avon Products Inc.和Computer Sciences Corporation的董事,两者都在纽约证券交易所(New York Stock Exchange)上市。她获得瓦萨尔学院(Vassar College)的学士学位和麻省理工学院斯隆管理学院(MIT Sloan School of Management)的工商管理硕士学位。
- Nancy Killefer,McKinsey & Company (international management consulting firm):Senior Partner (1992-2013),Governing Board Member (2000-2006 and 2007-2013),Head and Founder of global public sector practice (2005-2012),Head of Washington, D.C. office (2000-2007),Various other positions (1979-1992);U.S. Department of the Treasury:Assistant Secretary for Management, Chief Financial Officer & Chief Operating Officer (1997-2000);Education:Vassar College (B.A. in economics),Massachusetts Institute of Technology (M.S.M. in finance).
- Sudhakar Ramakrishna
-
Sudhakar Ramakrishna,担任SolarWinds公司的总裁兼首席执行官。在加入SolarWinds之前,2015年至2020年,Ramakrishna先生担任Pulse Secure,LLC的首席执行官。在加入Pulse Secure之前,Ramakrishna先生曾在思杰系统公司担任高级副总裁兼企业和服务提供商部门总经理,负责Citrix的虚拟化、云网络、移动平台和云服务解决方案组合。Ramakrishna先生还曾在Polycom、摩托罗拉和3Com担任高级领导职务。Ramakrishna先生自2021年6月以来一直担任领先的企业身份安全提供商SailPoint Technologies Holdings Inc.(NYSE:SAIL)的董事会成员。Ramakrishna先生拥有堪萨斯州立大学计算机科学硕士学位和西北大学家乐氏管理学院管理学硕士学位。
Sudhakar Ramakrishna,is a global technology leader with nearly 25 years of experience across cloud, mobility, networking, security, and collaboration markets. Since January 2021 Mr. Ramakrishna has served as President and Chief Executive Officer of SolarWinds Corporation, a software solution provider that helps businesses manage their network, systems and information technology infrastructure. Prior to SolarWinds, from 2015 to 2020 Mr. Ramakrishna served as the CEO of Pulse Secure, LLC, a provider of secure and zero trust access solutions for Hybrid IT environments, where he was responsible for all aspects of business strategy and execution. Prior to Pulse Secure, Mr. Ramakrishna served as the Senior Vice President and General Manager for the Enterprise and Service Provider Division at Citrix Systems, Inc., where he had responsibility for Citrix's portfolio of virtualization, cloud networking, mobile platforms, and cloud services solutions. Mr. Ramakrishna also has held senior leadership roles at Polycom, Motorola, and 3Com. Mr. Ramakrishna has served on the board of directors for SailPoint Technologies Holdings Inc. (NYSE: SAIL), a leading enterprise identity security provider since June 2021. Mr. Ramakrishna earned a M.S. in Computer Science from Kansas State University and a Master of Management from Northwestern University's Kellogg School of Management. - Sudhakar Ramakrishna,担任SolarWinds公司的总裁兼首席执行官。在加入SolarWinds之前,2015年至2020年,Ramakrishna先生担任Pulse Secure,LLC的首席执行官。在加入Pulse Secure之前,Ramakrishna先生曾在思杰系统公司担任高级副总裁兼企业和服务提供商部门总经理,负责Citrix的虚拟化、云网络、移动平台和云服务解决方案组合。Ramakrishna先生还曾在Polycom、摩托罗拉和3Com担任高级领导职务。Ramakrishna先生自2021年6月以来一直担任领先的企业身份安全提供商SailPoint Technologies Holdings Inc.(NYSE:SAIL)的董事会成员。Ramakrishna先生拥有堪萨斯州立大学计算机科学硕士学位和西北大学家乐氏管理学院管理学硕士学位。
- Sudhakar Ramakrishna,is a global technology leader with nearly 25 years of experience across cloud, mobility, networking, security, and collaboration markets. Since January 2021 Mr. Ramakrishna has served as President and Chief Executive Officer of SolarWinds Corporation, a software solution provider that helps businesses manage their network, systems and information technology infrastructure. Prior to SolarWinds, from 2015 to 2020 Mr. Ramakrishna served as the CEO of Pulse Secure, LLC, a provider of secure and zero trust access solutions for Hybrid IT environments, where he was responsible for all aspects of business strategy and execution. Prior to Pulse Secure, Mr. Ramakrishna served as the Senior Vice President and General Manager for the Enterprise and Service Provider Division at Citrix Systems, Inc., where he had responsibility for Citrix's portfolio of virtualization, cloud networking, mobile platforms, and cloud services solutions. Mr. Ramakrishna also has held senior leadership roles at Polycom, Motorola, and 3Com. Mr. Ramakrishna has served on the board of directors for SailPoint Technologies Holdings Inc. (NYSE: SAIL), a leading enterprise identity security provider since June 2021. Mr. Ramakrishna earned a M.S. in Computer Science from Kansas State University and a Master of Management from Northwestern University's Kellogg School of Management.
高管简历
中英对照 |  中文 |  英文- Jason M. Hollar
Jason M. Hollar, Cardinal Health首席执行官(自2022年起)。Cardinal Health首席财务官(2020 - 2022)。Tenneco Inc.(全球汽车产品和服务公司)的执行副总裁兼首席财务官(2018 - 2020)。Tenneco Inc.高级财务副总裁(2017 - 2018)。西尔斯控股公司(Sears Holding Corporation),一家美国大型消费零售商的控股公司(Sears于2018年10月申请破产保护)。他还曾担任Delphi Automotive's powertrain systems division的公司财务总监和财务副总裁,负责监督欧洲、中东和非洲地区。在职业生涯早期,他曾在Navistar的发动机集团、南美业务以及公司财务规划和分析担任财务职位,责任越来越大。
Jason M. Hollar,has served as Chief Executive Officer since September 2022. From May 2020 through August 2022, Mr. Hollar served as Chief Financial Officer. Additionally, Mr. Hollar served as Chief Financial Officer of Sears Holding Corporation ("Sears") from October 2016 to April 2017. Sears filed for Chapter 11 bankruptcy in October 2018.- Jason M. Hollar, Cardinal Health首席执行官(自2022年起)。Cardinal Health首席财务官(2020 - 2022)。Tenneco Inc.(全球汽车产品和服务公司)的执行副总裁兼首席财务官(2018 - 2020)。Tenneco Inc.高级财务副总裁(2017 - 2018)。西尔斯控股公司(Sears Holding Corporation),一家美国大型消费零售商的控股公司(Sears于2018年10月申请破产保护)。他还曾担任Delphi Automotive's powertrain systems division的公司财务总监和财务副总裁,负责监督欧洲、中东和非洲地区。在职业生涯早期,他曾在Navistar的发动机集团、南美业务以及公司财务规划和分析担任财务职位,责任越来越大。
- Jason M. Hollar,has served as Chief Executive Officer since September 2022. From May 2020 through August 2022, Mr. Hollar served as Chief Financial Officer. Additionally, Mr. Hollar served as Chief Financial Officer of Sears Holding Corporation ("Sears") from October 2016 to April 2017. Sears filed for Chapter 11 bankruptcy in October 2018.
- Stephen M. Mason
Stephen M. Mason 自 2019 年 8 月起担任医疗部门首席执行官。从 2016 年 9 月至 2019 年 8 月,他担任 Cardinal Health, Inc. 医疗部门的 Cardinal Health at-Home Solutions 总裁。
Stephen M. Mason,has served as Chief Executive Officer, GMPD segment since August 2019.- Stephen M. Mason 自 2019 年 8 月起担任医疗部门首席执行官。从 2016 年 9 月至 2019 年 8 月,他担任 Cardinal Health, Inc. 医疗部门的 Cardinal Health at-Home Solutions 总裁。
- Stephen M. Mason,has served as Chief Executive Officer, GMPD segment since August 2019.
- Deborah L. Weitzman
Deborah L. Weitzman,自2022年9月起担任制药部门的首席执行官。从2017年7月到2022年9月,她担任Cardinal Health, Inc.的总裁。药品分销部门。
Deborah L. Weitzman,has served as Chief Executive Officer, Pharma segment since September 2022. From July 2017 until September 2022, Ms. Weitzman served as the President of Pharmaceutical Distribution division.- Deborah L. Weitzman,自2022年9月起担任制药部门的首席执行官。从2017年7月到2022年9月,她担任Cardinal Health, Inc.的总裁。药品分销部门。
- Deborah L. Weitzman,has served as Chief Executive Officer, Pharma segment since September 2022. From July 2017 until September 2022, Ms. Weitzman served as the President of Pharmaceutical Distribution division.
- Aaron E. Alt
Aaron E. Alt自2020年12月起担任Sysco的执行副总裁兼首席财务官。此前,他曾担任Sally Beauty Holdings“SBH”(国际专业零售商和专业美容用品分销商)的高级副总裁兼首席财务官,以及Sally Beauty Supply(全球最大的专业美容用品零售商,总部位于达拉斯)的总裁(2018年10月以来)。此前,从2018年5月到2018年10月,他担任SBH的高级副总裁、首席财务官和首席行政官。在加入SBH之前,他曾担任Target Corporation(一家美国零售公司和美国第二大折扣零售商)的多种行政领导职务,包括运营高级副总裁(2017年3月至2018年5月);2016年1月至2017年3月担任食品杂货转型高级副总裁;2015年1月至2018年5月,担任Target Canada Co.的首席执行官;2015年8月至2016年1月,担任财务高级副总裁;2015年3月至2015年8月,担任高级副总裁,税务和财务主管;2013年10月至2015年3月,担任业务发展、风险管理、税务和财务高级副总裁;2012年9月至2013年10月,担任高级副总裁,业务发展和财务主管。加入Target Corporation之前,2004年至2012年,他在Sara Lee Corporation担任多个高级职位。2003年至2004年,他是伦敦Kirkland & Ellis律师事务所的合伙人。他持有Harvard Law School的法学博士学位,Northwestern University的J.L. Kellogg School of Management的工商管理硕士学位,以及Northwestern University的历史和政治科学学士学位。
Aaron E. Alt,has served as Chief Financial Officer since February 2023. Prior to that, Mr. Alt served as Executive Vice President and Chief Financial Officer of Sysco Corporation from December 2020. From October 2018 to November 2020, Mr. Alt served as Senior Vice President and Chief Financial Officer of Sally Beauty Holdings, Inc. and President of Sally Beauty Supply.- Aaron E. Alt自2020年12月起担任Sysco的执行副总裁兼首席财务官。此前,他曾担任Sally Beauty Holdings“SBH”(国际专业零售商和专业美容用品分销商)的高级副总裁兼首席财务官,以及Sally Beauty Supply(全球最大的专业美容用品零售商,总部位于达拉斯)的总裁(2018年10月以来)。此前,从2018年5月到2018年10月,他担任SBH的高级副总裁、首席财务官和首席行政官。在加入SBH之前,他曾担任Target Corporation(一家美国零售公司和美国第二大折扣零售商)的多种行政领导职务,包括运营高级副总裁(2017年3月至2018年5月);2016年1月至2017年3月担任食品杂货转型高级副总裁;2015年1月至2018年5月,担任Target Canada Co.的首席执行官;2015年8月至2016年1月,担任财务高级副总裁;2015年3月至2015年8月,担任高级副总裁,税务和财务主管;2013年10月至2015年3月,担任业务发展、风险管理、税务和财务高级副总裁;2012年9月至2013年10月,担任高级副总裁,业务发展和财务主管。加入Target Corporation之前,2004年至2012年,他在Sara Lee Corporation担任多个高级职位。2003年至2004年,他是伦敦Kirkland & Ellis律师事务所的合伙人。他持有Harvard Law School的法学博士学位,Northwestern University的J.L. Kellogg School of Management的工商管理硕士学位,以及Northwestern University的历史和政治科学学士学位。
- Aaron E. Alt,has served as Chief Financial Officer since February 2023. Prior to that, Mr. Alt served as Executive Vice President and Chief Financial Officer of Sysco Corporation from December 2020. From October 2018 to November 2020, Mr. Alt served as Senior Vice President and Chief Financial Officer of Sally Beauty Holdings, Inc. and President of Sally Beauty Supply.
- Ola M. Snow
Ola M. Snow自2018年10月以来一直担任首席人力资源官。从2016年1月至2018年9月,Snow女士担任人力资源,总薪酬,人才获取和企业业务合作伙伴高级副总裁。从2012年11月到2016年1月,她担任医疗部门人力资源高级副总裁。
Ola M. Snow,as served as Chief Human Resources Officer since October 2018.- Ola M. Snow自2018年10月以来一直担任首席人力资源官。从2016年1月至2018年9月,Snow女士担任人力资源,总薪酬,人才获取和企业业务合作伙伴高级副总裁。从2012年11月到2016年1月,她担任医疗部门人力资源高级副总裁。
- Ola M. Snow,as served as Chief Human Resources Officer since October 2018.
- Jessica L. Mayer
Jessica L. Mayer自2019年3月以来一直担任首席法律与合规官。梅耶女士从2017年9月至2019年3月担任执行副总裁,副总法律顾问兼秘书。从2015年12月至2017年9月,梅耶女士担任高级副总裁。总裁,副总法律顾问,从2008年6月至2015年12月,她担任常务副总裁。
Jessica L. Mayer,has served as Chief Legal and Compliance Officer since March 2019.- Jessica L. Mayer自2019年3月以来一直担任首席法律与合规官。梅耶女士从2017年9月至2019年3月担任执行副总裁,副总法律顾问兼秘书。从2015年12月至2017年9月,梅耶女士担任高级副总裁。总裁,副总法律顾问,从2008年6月至2015年12月,她担任常务副总裁。
- Jessica L. Mayer,has served as Chief Legal and Compliance Officer since March 2019.
- Michelle D. Greene
Michelle D. Greene,自2022年8月起担任执行副总裁、首席信息官和客户支持服务。从2021年2月到2022年8月,她担任制药部门信息技术高级副总裁。在加入Cardinal Health之前,她于2018年3月至2021年2月担任Masco Corporation的信息技术副总裁。
Michelle D. Greene,has served as Executive Vice President, Chief Information Officer, and Customer Support Services since August 2022. From February 2021 until August 2022, Ms. Greene served as the Senior Vice President of former Pharmaceutical segment Information Technology. Prior to joining Cardinal Health, Ms. Greene served as Vice President, Information Technology, at Masco Corporation from March 2018 through February 2021.- Michelle D. Greene,自2022年8月起担任执行副总裁、首席信息官和客户支持服务。从2021年2月到2022年8月,她担任制药部门信息技术高级副总裁。在加入Cardinal Health之前,她于2018年3月至2021年2月担任Masco Corporation的信息技术副总裁。
- Michelle D. Greene,has served as Executive Vice President, Chief Information Officer, and Customer Support Services since August 2022. From February 2021 until August 2022, Ms. Greene served as the Senior Vice President of former Pharmaceutical segment Information Technology. Prior to joining Cardinal Health, Ms. Greene served as Vice President, Information Technology, at Masco Corporation from March 2018 through February 2021.
- Mary C. Scherer
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介